HOME >> BIOLOGY >> NEWS
Modeling lung cancer

In a new report in the February 15th issue of G&D, Dr. Martin McMahon (UCSF) and colleagues present a novel mouse model of non-small cell lung cancer, which will serve as a useful tool to test the efficacy of novel chemotherapeutic drug therapies in the early stages of lung tumorigenesis. Their paper provides evidence to support the use of a relatively new class of drugs, called MEK inhibitors, for lung cancer patients whose tumors contain mutations in the BRaf gene.

BRaf is one of three members of the RAF kinase family, which, upon activation, induces the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) cell signaling pathway and promotes cell proliferation. Activating mutations in BRaf (ie., a mutation that causes the activation of the catalytic activity of the BRaf protein) are implicated in a number of different human cancers, including the majority of melanoma cancers, as well as in colorectal, thyroid, ovarian and non-small cell lung cancers.

Dr. McMahon and colleagues engineered a strain of mice to carry a version of the BRaf gene that the researchers could activate at will both temporally and spatially. After activating BRaf specifically in the lungs of mice at 6-8 weeks of age, the researchers observed that the BRaf-mutant mice (or BRaf(VE), as they are known) developed multiple lung tumors that were pathologically similar to human lung tumors thereby establishing BRaf as a bona fide oncoprotein.

Administration of the MEK-inhibitor, PD0325901 (developed by Pfizer, and now in clinical trials) effectively halted tumor progression in BRaf(VE) mice. Interestingly, however, without pharmacological intervention, the BRaf-mutant tumors eventually stopped proliferating, and entered into a senescent state. This senescent state could be overcome by concomitant mutation of either p53 or p16(Ink4a)/p19(Arf), enabling tumors to become adenocarcinomas.

Dr. McMahon said that the striking response
'"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
12-Feb-2007


Page: 1 2

Related biology news :

1. Modeling the restless brain
2. Modeling alien invasions: Plasticity may hold the key to prevention
3. Symposium Environmental Change in Siberia -- Insights From Earth Observation and Modeling
4. Burnham Institute for Medical Research & UC San Diego establish Joint Center for Molecular Modeling
5. Students from U of Colorado at Boulder and Harvard triumph in SIAMs Math Contest in Modeling
6. Modeling head and neck cancers
7. Protein chatter linked to cancer activation
8. Newly created cancer stem cells could aid breast cancer research
9. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
10. ESF EURYI award winner aims to stop cancer cells reading their own DNA
11. No evidence that widely prescribed statins protect against prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Modeling lung cancer

(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, Ltd. ... an agreement with Novella Clinical (Novella), to ... patients with newly diagnosed glioblastoma. Novella is a full-service, ... to small to mid-sized oncology companies. The ICT-107 phase ... the US, Europe and ...
(Date:7/3/2015)... , July 3, 2015 ... voivat hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Open Innovation in Science" -jatkokoulutusohjelmaan ... Boltzmann Gesellschaftin (LBG) tekemän, kansainvälisiä ... mukaan terveystieteiden kaksi suurinta haastetta ...
(Date:7/3/2015)... , July 3, 2015 ... till 22 september 2015 på  http://www.openinnovationinscience.at ... Innovation in Science" som hålls i ... en färsk undersökning med internationella forskare och ... (LBG) är hälsovetenskapens två största utmaningar bristen ...
(Date:7/3/2015)... WIEN , July 3, 2015 /PRNewswire/ ... indtil den 22. september 2015 på  http://www.openinnovationinscience.at ... in Science", der finder sted i ... en nylig undersøgelse af internationale forskere og ... er de to største udfordringer for sundhedsvidenskaben ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
Cached News: